{"id":"control-ufh","safety":{"commonSideEffects":[{"rate":"1-10%","effect":"Bleeding"},{"rate":"0.5-3%","effect":"Heparin-induced thrombocytopenia (HIT)"},{"rate":"0.5-2%","effect":"Thrombosis"},{"rate":null,"effect":"Osteoporosis (with prolonged use)"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL1643772","moleculeType":"Small molecule","molecularWeight":"494.57"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"UFH works by binding to and enhancing the activity of antithrombin III, a natural inhibitor of coagulation. This complex inactivates several key clotting factors (particularly factors IIa and Xa), preventing the formation and extension of fibrin clots. UFH is administered intravenously or subcutaneously and has a rapid onset of action, making it suitable for acute thrombotic conditions.","oneSentence":"Unfractionated heparin (UFH) is an anticoagulant that inhibits multiple clotting factors to prevent blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:45:21.500Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute venous thromboembolism (DVT/PE) treatment and prevention"},{"name":"Acute coronary syndrome"},{"name":"Atrial fibrillation with thromboembolism risk"},{"name":"Cardiopulmonary bypass anticoagulation"}]},"trialDetails":[{"nctId":"NCT05848713","phase":"PHASE3","title":"AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2023-10-10","conditions":"Community-acquired Pneumonia","enrollment":4000},{"nctId":"NCT07352800","phase":"PHASE2","title":"Safety of Antithrombotic Heparin Proteoglycan Mimetic APAC in Peripheral Arterial Occlusive Disease and Chronic Limb-threatening Ischemia","status":"RECRUITING","sponsor":"Aplagon Oy","startDate":"2026-01-29","conditions":"Peripheral Arterial Occlusive Disease, Chronic Limb-Threatening Ischemia","enrollment":42},{"nctId":"NCT07361783","phase":"NA","title":"Impact of Pre-Hospital Heparin Loading in STEMI Patients for Primary PCI: The HELP-PCI 2 Trial","status":"RECRUITING","sponsor":"Chen Jing","startDate":"2025-08-13","conditions":"Primary PCI, ST-elevation Myocardial Infarction (STEMI)","enrollment":6294},{"nctId":"NCT05684796","phase":"NA","title":"Comparison of Two Pulmonary Embolism Treatments","status":"COMPLETED","sponsor":"Penumbra Inc.","startDate":"2023-11-27","conditions":"Pulmonary Embolism Acute","enrollment":100},{"nctId":"NCT04545541","phase":"PHASE2, PHASE3","title":"Nebulised Heparin in Patients With Severe COVID-19","status":"COMPLETED","sponsor":"Australian National University","startDate":"2020-11-01","conditions":"Covid19, Respiratory Failure","enrollment":57},{"nctId":"NCT07214103","phase":"PHASE2","title":"Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients With Septic Coagulopathy","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2026-03-01","conditions":"Septic Shock, Coagulopathy","enrollment":120},{"nctId":"NCT07032025","phase":"EARLY_PHASE1","title":"Mechanical Thrombectomy for Acute Pulmonary Embolism","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-07-01","conditions":"Acute Pulmonary Embolism","enrollment":200},{"nctId":"NCT04924322","phase":"PHASE2, PHASE3","title":"Catheter-Related Early Thromboprophylaxis With Enoxaparin Studies","status":"RECRUITING","sponsor":"Yale University","startDate":"2022-05-11","conditions":"Deep Venous Thrombosis","enrollment":258},{"nctId":"NCT05247424","phase":"PHASE4","title":"Pretreatment With Unfractionated Heparin for ST Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2022-03-10","conditions":"STEMI - ST Elevation Myocardial Infarction","enrollment":600},{"nctId":"NCT05204550","phase":"PHASE2, PHASE3","title":"Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children","status":"ACTIVE_NOT_RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2023-01-30","conditions":"COVID-19","enrollment":506},{"nctId":"NCT05726825","phase":"NA","title":"Efficacy of Add-on Plasma Exchange As an Adjunctive Strategy Against Septic Shock","status":"RECRUITING","sponsor":"Hannover Medical School","startDate":"2025-02-19","conditions":"Septic Shock","enrollment":274},{"nctId":"NCT05208112","phase":"PHASE1","title":"Intravenously Administered M6229 in Critically Ill Sepsis Patients","status":"COMPLETED","sponsor":"A.P.J. Vlaar","startDate":"2022-04-05","conditions":"Sepsis, Septic Shock, Critical Illness","enrollment":10},{"nctId":"NCT04362085","phase":"PHASE3","title":"Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care","status":"COMPLETED","sponsor":"Unity Health Toronto","startDate":"2020-05-11","conditions":"COVID-19","enrollment":465},{"nctId":"NCT06442267","phase":"PHASE4","title":"Comparing Anticoagulation Strategies Using UFH, Argatroban and LMWH for ECMO Support","status":"RECRUITING","sponsor":"Medical University of Vienna","startDate":"2024-07-30","conditions":"Respiratory Insufficiency, Circulatory Failure, Thromboembolism","enrollment":90},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT05148026","phase":"NA","title":"Regional Citrate Anticoagulation for RRT During V-V ECMO","status":"RECRUITING","sponsor":"University of Milano Bicocca","startDate":"2021-11-14","conditions":"ARDS, Human, Acute Kidney Injury","enrollment":20},{"nctId":"NCT06375616","phase":"PHASE4","title":"Comparison of Nafamostat and Unfractionated Heparin in RRT for Sepsis Associated AKI","status":"NOT_YET_RECRUITING","sponsor":"Shen Lei","startDate":"2024-04","conditions":"Sepsis","enrollment":156},{"nctId":"NCT04925167","phase":"NA","title":"Safety and Efficacy of Argatroban Applicated in Anticoagulation of V-V ECMO","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2021-07-06","conditions":"Respiratory Failure","enrollment":20},{"nctId":"NCT04409834","phase":"PHASE4","title":"Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial","status":"COMPLETED","sponsor":"The TIMI Study Group","startDate":"2020-08-05","conditions":"COVID-19, Venous Thromboembolism, Arterial Thrombosis","enrollment":390},{"nctId":"NCT03083184","phase":"PHASE3","title":"Evaluation of the Efficacy of an inTerdialytic \"Ethanol 40% v/v - enoxapaRin 1000 U/mL\" Lock solutioN to Prevent Tunnelled Catheter Infections in Chronic Hemodialysis Patients","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2018-02-09","conditions":"Tunnelled Hemodialysis Catheter Infection","enrollment":400},{"nctId":"NCT04569279","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin in CVT Treatment","status":"COMPLETED","sponsor":"Damascus University","startDate":"2017-09-01","conditions":"Cerebral Vein Thrombosis","enrollment":71},{"nctId":"NCT05671250","phase":"PHASE2","title":"Bioactive Smart Dressings for Diabetic Foot Ulcers: Randomized Controlled Trial","status":"COMPLETED","sponsor":"Mansoura University","startDate":"2021-07-15","conditions":"Diabetic Foot Ulcer","enrollment":30},{"nctId":"NCT02664155","phase":"PHASE3","title":"Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2016-10-19","conditions":"Renal Insufficiency","enrollment":203},{"nctId":"NCT01442792","phase":"PHASE2","title":"Exploring the Efficacy and Safety of Rivaroxaban to Support Elective Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-10-12","conditions":"Cardiovascular Disease, Coronary Artery Disease","enrollment":108},{"nctId":"NCT04357730","phase":"PHASE2","title":"Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection","status":"COMPLETED","sponsor":"Denver Health and Hospital Authority","startDate":"2020-05-14","conditions":"Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome","enrollment":50},{"nctId":"NCT04444700","phase":"PHASE3","title":"A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic","status":"COMPLETED","sponsor":"University of Sao Paulo General Hospital","startDate":"2020-07-04","conditions":"COVID, Coronavirus Infection, Severe Acute Respiratory Syndrome","enrollment":465},{"nctId":"NCT04372589","phase":"PHASE2, PHASE3","title":"Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC)","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2020-05-20","conditions":"COVID-19, Pneumonia","enrollment":1200},{"nctId":"NCT02098993","phase":"PHASE2","title":"Feasibility Study of Unfractionated Heparin in Acute Chest Syndrome","status":"TERMINATED","sponsor":"Craig Seaman","startDate":"2014-05","conditions":"Acute Chest Syndrome, Sickle Cell Disease","enrollment":7},{"nctId":"NCT00981409","phase":"PHASE3","title":"The Treatment of Acute Pulmonary Thromboembolism (PE) of GSK576428 (Fondaparinux Sodium) in Japanese Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07","conditions":"Embolism, Pulmonary","enrollment":41},{"nctId":"NCT00911157","phase":"PHASE3","title":"The Treatment of Acute Deep Vein Thrombosis (DVT) of GSK576428 (Fondaparinux Sodium) in Japanese Patients","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-06","conditions":"Thrombosis, Venous","enrollment":39},{"nctId":"NCT00064428","phase":"PHASE3","title":"OASIS-6 : The Safety and Efficacy of Fondaparinux Versus Control Therapy in Patients With ST Segment Elevation Acute Myocardial Infarction","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-08","conditions":"Thromboembolism","enrollment":12092},{"nctId":"NCT01780987","phase":"PHASE3","title":"AStudy To Evaluate Safety And Eficacy Of Apixaban In Japanese Acute Deep Vein Thrombosis (DVT) And Pulmonary Embolism (PE) Patients","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-01","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":80},{"nctId":"NCT02763839","phase":"PHASE1","title":"Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Carbidopa (100/25 mg)","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2001-04","conditions":"Parkinson's Disease","enrollment":19},{"nctId":"NCT02763852","phase":"PHASE1","title":"Pharmacokinetic-Pharmacodynamic Interaction Between Four Different Single Doses of BIA 3-202 and a Single Dose of Levodopa/Benserazide (100/25 mg)","status":"COMPLETED","sponsor":"Bial - Portela C S.A.","startDate":"2001-04","conditions":"Parkinson's Disease","enrollment":18},{"nctId":"NCT01087723","phase":"PHASE3","title":"European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2010-03","conditions":"Acute Coronary Syndrome","enrollment":2198},{"nctId":"NCT01519518","phase":"PHASE4","title":"How Effective Are Antithrombotic Therapies in Primary Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Liverpool Heart and Chest Hospital NHS Foundation Trust","startDate":"2012-02","conditions":"Acute ST Elevation Myocardial Infarction","enrollment":1829},{"nctId":"NCT00317395","phase":"PHASE2","title":"Study of Otamixaban Versus Unfractionated Heparin (UFH) and Eptifibatide in Non-ST Elevation Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-06","conditions":"Coronary Disease","enrollment":3241},{"nctId":"NCT02294994","phase":"PHASE4","title":"Efficacy and Safety of Different Dose of Tirofiban in Interventional Treatment of Complex Coronary Artery Disease","status":"UNKNOWN","sponsor":"Second Hospital of Jilin University","startDate":"2014-11","conditions":"Coronary Artery Disease","enrollment":1000},{"nctId":"NCT01465503","phase":"PHASE3","title":"Novel Approaches in Preventing and Limiting Events III Trial (NAPLES III): Bivalirudin in High-risk Bleeding Patients","status":"COMPLETED","sponsor":"Clinica Mediterranea","startDate":"2008-01","conditions":"Bleeding","enrollment":837},{"nctId":"NCT00373451","phase":"PHASE4","title":"Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary Syndrome","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2006-07","conditions":"Myocardial Infarction, Coronary Disease","enrollment":1721},{"nctId":"NCT01051778","phase":"PHASE2","title":"Low-molecular-weight Heparin (LMWH) Versus Unfractionated Heparin (UFH) in Pregnant Women With Recurrent Abortion Secondary to Antiphospholipid Syndrome","status":"COMPLETED","sponsor":"Cairo University","startDate":"2006-06","conditions":"Recurrent Abortion","enrollment":60},{"nctId":"NCT00262054","phase":"PHASE4","title":"Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)","status":"COMPLETED","sponsor":"Deutsches Herzzentrum Muenchen","startDate":"2005-11","conditions":"Coronary Disease, Angina Pectoris","enrollment":4570},{"nctId":"NCT00796692","phase":"PHASE4","title":"Nadroparin for the Initial Treatment of Pulmonary Thromboembolism","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2002-06","conditions":"Pulmonary Embolism, Thromboembolism, Vascular Diseases","enrollment":274},{"nctId":"NCT00182364","phase":"PHASE3","title":"PROphylaxis for ThromboEmbolism in Critical Care Trial (PROTECT Pilot)","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","startDate":"2003-02","conditions":"Critically Ill, Deep Venous Thrombosis","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":993,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Control - UFH","genericName":"Control - UFH","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Unfractionated heparin (UFH) is an anticoagulant that inhibits multiple clotting factors to prevent blood clot formation. Used for Acute venous thromboembolism (DVT/PE) treatment and prevention, Acute coronary syndrome, Atrial fibrillation with thromboembolism risk.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}